CINECA IRIS Institutional Research Information System

SALANI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.091
AS - Asia 2.134
EU - Europa 1.255
SA - Sud America 290
Continente sconosciuto - Info sul continente non disponibili 163
AF - Africa 129
OC - Oceania 5
Totale 7.067
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.999
SG - Singapore 809
CN - Cina 552
IT - Italia 481
HK - Hong Kong 246
BR - Brasile 225
SE - Svezia 194
VN - Vietnam 181
DE - Germania 106
GB - Regno Unito 94
FR - Francia 57
IN - India 57
CI - Costa d'Avorio 54
JP - Giappone 52
KR - Corea 50
FI - Finlandia 49
AT - Austria 46
NL - Olanda 46
RU - Federazione Russa 44
BG - Bulgaria 39
CA - Canada 34
BD - Bangladesh 31
AR - Argentina 28
IQ - Iraq 26
MX - Messico 25
PL - Polonia 22
TR - Turchia 20
NG - Nigeria 19
PK - Pakistan 14
ES - Italia 12
ID - Indonesia 12
SN - Senegal 12
UA - Ucraina 12
VE - Venezuela 12
LT - Lituania 11
ZA - Sudafrica 11
CH - Svizzera 9
KE - Kenya 9
UZ - Uzbekistan 9
CR - Costa Rica 8
JO - Giordania 8
MY - Malesia 8
SA - Arabia Saudita 8
EC - Ecuador 7
BE - Belgio 6
CO - Colombia 6
CZ - Repubblica Ceca 6
LB - Libano 6
RO - Romania 6
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
PH - Filippine 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
NP - Nepal 4
PS - Palestinian Territory 4
SV - El Salvador 4
AL - Albania 3
IE - Irlanda 3
JM - Giamaica 3
KZ - Kazakistan 3
OM - Oman 3
PE - Perù 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GD - Grenada 2
HN - Honduras 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
TH - Thailandia 2
UY - Uruguay 2
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
DM - Dominica 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
NO - Norvegia 1
Totale 6.896
Salva come PNG Salva come JPEG
Città #
Singapore 465
Ashburn 385
San Jose 364
Hong Kong 240
Dallas 220
Santa Clara 203
Shanghai 117
Council Bluffs 93
Chandler 90
Los Angeles 87
New York 81
Hefei 80
Milan 78
Beijing 66
Boardman 63
Fairfield 55
Abidjan 54
Munich 52
Seoul 48
Ho Chi Minh City 46
Tokyo 45
Florence 44
London 39
Sofia 39
Hanoi 38
Seattle 34
Vienna 32
Buffalo 28
Pisa 25
Lauterbourg 24
Colorado Springs 23
Turku 22
Frankfurt am Main 20
Woodbridge 20
Lagos 19
Lawrence 18
Princeton 18
Warsaw 18
Cambridge 17
Houston 17
Memphis 17
Wilmington 17
Helsinki 16
Redondo Beach 16
Hyderabad 15
Orem 15
Rome 15
Baghdad 14
Istanbul 13
Kent 13
Montreal 13
Nuremberg 13
São Paulo 13
Atlanta 12
Da Nang 12
Dakar 12
Ogden 12
Brooklyn 11
Medford 11
Baltimore 10
Boston 10
Chennai 10
Chicago 10
Denver 10
Düsseldorf 10
Lappeenranta 10
Mexico City 10
Quanzhou 10
San Diego 9
Tashkent 9
Amman 8
Cascina 8
Columbus 8
Curitiba 8
Haiphong 8
Portsmouth 8
Stockholm 8
Ann Arbor 7
Fuzhou 7
Guangzhou 7
Nairobi 7
Philadelphia 7
Phoenix 7
Poplar 7
Salt Lake City 7
The Dalles 7
Turin 7
Amsterdam 6
Dhaka 6
Jeddah 6
Karachi 6
Naples 6
Rio de Janeiro 6
Zurich 6
Goiânia 5
Hải Dương 5
Miami 5
Newark 5
Norwalk 5
Salvador 5
Totale 3.993
Salva come PNG Salva come JPEG
Nome #
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 291
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 189
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 176
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 173
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 169
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 163
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 160
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 155
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 154
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 152
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 152
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 145
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 143
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 142
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 141
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 139
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 139
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 136
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 133
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 130
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 126
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 124
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 122
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 121
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 120
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 119
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 118
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 118
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 106
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study 103
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 102
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 101
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 96
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 96
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 93
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 90
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 89
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 87
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 86
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 82
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 80
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 80
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 76
Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions 76
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 74
In Reply 74
Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights 72
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 70
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 66
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 63
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 62
null 59
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 56
Comprehensive analysis of differentially expressed miRNAs in Hepatocellular carcinoma: prognostic significance and pathway insights 55
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings 51
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 49
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 48
null 48
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 46
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 44
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 40
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 40
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 38
Precision epigenetic therapies in oncology 36
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 35
null 34
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study 31
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 31
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 30
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings 26
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 23
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 22
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 18
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis 13
Totale 7.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022204 0 1 3 6 42 41 6 2 19 14 22 48
2022/2023465 50 70 34 15 51 59 6 36 94 2 39 9
2023/2024424 21 41 42 26 58 40 65 16 5 17 41 52
2024/20251.999 14 99 46 84 151 310 132 96 172 193 264 438
2025/20263.210 233 314 270 248 348 245 520 216 197 342 186 91
2026/2027593 171 422 0 0 0 0 0 0 0 0 0 0
Totale 7.067